Zygote
The computed 12-month bankruptcy probability of Zygote is 0.6% (low). The 2024 annual accounts show equity of €4k and a net result of €-219k. Equity is shrinking by ~46.3% per year and would, assuming unchanged policy, indicatively turn negative around fiscal year 2025. Its solvency ranks better than 23% of 561 sector peers (fiscal year 2024). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €4k |
| Net result | €-219k |
| Staff (FTE) | 8.9 |
| Better than sector | 23% |
Fragile profile, watch health in particular.
All 5 axes are computed from data Checked has read.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 1.1% | 34.8% | |
| Net result | €-219k | €15k | |
| Equity | €4k | €79k | |
| Gross operating margin | €473k | €81k | |
| Staff costs | €666k | €297k |
| Fiscal year | 2024 |
|---|---|
| Deposit | verkort |
| Revenue | €1.07M |
| EBITDA | €-197k |
| Net profit | €-219k |
| Cash flow | €-215k |
| Staff costs | €666k |
| Income taxes | €2k |
| Dividends | - |
| Total assets | €367k |
| Equity | €4k |
| Debt | €363k |
| of which ≤ 1y | €363k |
| of which > 1y | - |
| Working capital | €-12k |
| Employees (FTE) | 8.9 |
| 2024 | |
|---|---|
| Current ratio | 0.97 |
| Quick ratio | 0.97 |
| Working capital ratio | -3.2% |
| Solvency | 1.1% |
| Debt / equity | 93.84 |
| Long-term debt ratio | - |
| Interest coverage | -11.51 |
| Gross margin | 40.7% |
| Net margin | -20.5% |
| ROA | -59.7% |
| ROE | -5659.1% |
| EBITDA margin | -18.4% |
| Days sales outstanding | 110d |
| Days payable outstanding | 61d |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €367k |
| Fixed assets | 21/28 | €16k |
| Tangible fixed assets | 22/27 | €16k |
| Current assets | 29/58 | €351k |
| Amounts receivable within one year | 40/41 | €322k |
| Cash & bank | 54/58 | €12k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €367k |
| Equity | 10/15 | €4k |
| Contributions / capital | 10/11 | €250k |
| Accumulated profits (losses) | 14 | €-246k |
| Amounts payable | 17/49 | €363k |
| Amounts payable within one year | 42/48 | €363k |
| Trade debts payable within one year | 44 | €106k |
| Income statement | ||
| Turnover | 70 | €1.07M |
| Gross operating margin | 9900 | €473k |
| Operating result | 9901 | €-200k |
| Financial income | 75 | €422 |
| Financial charges | 65 | €17k |
| Result before taxes | 9903 | €-217k |
| Income taxes | 67/77 | €2k |
| Net result for the period | 9904 | €-219k |
| Result to be appropriated | 9905 | €-219k |
-
Current21-03-2023 → present
Former directors (2)
-
Former- → 21-03-2023
-
Divirsiti NVLegal entityDirector· perm. rep.: Wim BijnensState Gazette act 22043851 (05-04-2022)Former- → 17-02-2022
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| KPMG Bedrijfsrevisoren BVCurrent Statutory auditor · represented by Dieter Vanloock |
- | 14-05-2025 → present |
| KPMG Bedrijfsrevisoren CVBA Statutory auditor · represented by Filip De Bock |
- | - → 01-01-2022 |
| NACE primary | Activiteiten op het gebied van computerconsultancy en beheer van computerfaciliteiten(62200) |
| Legal form | Public limited company(014) |
| Incorporation | 13-09-2021 |
| Status | Active |
| Postal code | 2550 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11024B0079/00F000 | Flanders | 3,333 m² | 1 · 932 m² | 10.3 m · 3 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
24-10-2025 Dieter Vanloock reappointed as statutory auditor
- Dieter Vanloock, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_renew",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Dieter Vanloock",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "KPMG Bedrijfsrevisoren BV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2025-05-14",
"evidence_quote": "Volgend op het voorstel van het bestuursorgaan, beslist de Algemene Vergadering der Aandeelhouders om KPMG Bedrijfsrevisoren BV, vertegenwoordigd door Dieter Vanloock, kantoorhoudend te 1930 Zaventem, Luchthaven Brussel Nationaal 1K te herbenoemen tot commissaris en dit met onmiddellijke ingang voor"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0773.774.443",
"name_full": "ZYGOTE",
"legal_form": "NV"
}
}31-08-2023 Capital increase of €188,000 to €250,000
- €62.000 → €250.000
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 188000.0,
"currency": "EUR",
"after_eur": 250000.0,
"delta_eur": 188000.0,
"before_eur": 62000.0,
"amount_type": "kapitaal_effectief",
"effective_date": "2023-08-17",
"evidence_quote": "het kapitaal van de vennootschap verhoogd werd door inbreng in geld met een bedrag van honderd achtentachtigduizend euro (\u20AC 188.000,00) om het te brengen van twee\u00EBnzestigduizend euro (\u20AC 62.000,00) op tweehonderd vijftigduizend euro (\u20AC 250.000,00)",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0773.774.443",
"name_full": "LIFESCIENCES INJECTR",
"legal_form": "BV"
}
}24-05-2023 1 director appointed, 1 resigning
- Ans Anthonis, Bestuurder
- Thierri Callaerts, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Ans Anthonis",
"address": null,
"birth_date": null
},
"effective_date": "2023-03-21",
"evidence_quote": "Het bestuursorgaan heeft vastgesteld dat Crosspoint Solutions NV voor wat betreft de uitoefening van haar mandaat van bestuurder van de Vennootschap, heef besloten om Thierri Callaerts, als vaste vertegenwoordiger per 21 maart 2023 te vervangen door Ans Anthonis."
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Thierri Callaerts",
"address": null,
"birth_date": null
},
"effective_date": "2023-03-21",
"evidence_quote": "Het bestuursorgaan heeft vastgesteld dat Crosspoint Solutions NV voor wat betreft de uitoefening van haar mandaat van bestuurder van de Vennootschap, heef besloten om Thierri Callaerts, als vaste vertegenwoordiger per 21 maart 2023 te vervangen door Ans Anthonis."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0773.774.443",
"name_full": "LIFESCIENCES INJECTR",
"legal_form": "BV"
}
}11-04-2023 Filip De Bock resigns as statutory auditor
- Filip De Bock, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_out",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Filip De Bock",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "KPMG Bedrijfsrevisoren CVBA",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2022-01-01",
"evidence_quote": "De Algemene Vergadering bevestigt met \u00E9\u00E9nparigheid van stemmen de kennisname van het feit dat de heer Filip De Bock, bedrijfsrevisor, werd vervangen als vaste vertegenwoordiger van de commissaris van de Vennootschap, te weten KPMG Bedrijfsrevisoren CVBA, kantoorhoudend te Luchthaven Brussel Nationaa"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0773.774.443",
"name_full": "LIFESCIENCES INJECTR",
"legal_form": "BV"
}
}05-04-2022 Wim Bijnens resigns as director
- Wim Bijnens, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Wim Bijnens",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Divirsiti NV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2022-02-17",
"evidence_quote": "De aandeelhouders hebben kennis genomen van het ontslag van Divirsiti NV, vast vertegenwoordigd door Wim Bijnens, als bestuurder van de Vennootschap, met ingang vanaf 17 februari 2022. Met unanimiteit van stemmen bevestigen zij dit ontslag. De aandeelhouders besluiten, bij aparte stemming en voor zo",
"discharge_granted": true
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0773.774.443",
"name_full": "LIFESCIENCES INJECTR",
"legal_form": "BV"
}
}15-09-2021 Incorporation of a new NV
Technical details
{
"kind": "oprichting",
"seat": "2550 Kontich, Veldkant 33 A",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": {
"kbo": "0664.942.225",
"name": "Divirsiti"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "Ordinary",
"partner_role": null,
"holder_org_kbo": "0664.942.225",
"holder_org_name": "Divirsiti",
"contribution_type": "cash",
"amount_paid_in_eur": 31000,
"holder_person_name": null,
"is_subscriber_only": true,
"n_shares_subscribed": 3100,
"amount_subscribed_eur": 31000,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": "0881.854.615",
"name": "CrossPoint Solutions"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "Ordinary",
"partner_role": null,
"holder_org_kbo": "0881.854.615",
"holder_org_name": "CrossPoint Solutions",
"contribution_type": "cash",
"amount_paid_in_eur": 31000,
"holder_person_name": null,
"is_subscriber_only": true,
"n_shares_subscribed": 3100,
"amount_subscribed_eur": 31000,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 62000,
"subject_company": {
"kbo": "0773.774.443",
"name_full": "LifeSciences Injectr",
"legal_form": "NV"
},
"initial_directors": [],
"incorporation_date": "2021-09-08",
"post_incorporation_mandates": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | Zygote |